Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01896999)
This phase I trial studies the side effects and best dose of ipilimumab when given together with brentuximab vedotin (also known as SGN-035) in treating patients with Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Monoclonal antibodies, such as ipilimumab and brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread.
This trial is sponsored by The National Cancer Institute (NCI). 
- Condition: Hodgkin Lymphoma
- Phase: I
- Estimated Enrollment: 70
- Start: January 2014
- Estimated Primary Completion: March 2016 (Final data collection date for primary outcome measure)
- Last verified: February 2015
Last Editorial review: July 25, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.